<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01557140</url>
  </required_header>
  <id_info>
    <org_study_id>Carvedilol in Chagas disease</org_study_id>
    <nct_id>NCT01557140</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy</brief_title>
  <official_title>A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Minas Gerais</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Chagas cardiomyopathy causes substantial morbidity and mortality in Latin America.&#xD;
      Whether RAS inhibitors and beta-blockers are safe and beneficial has been challenged because&#xD;
      of the lack of formal trials. Hence, the objective of this study was to determine the safety&#xD;
      and efficacy of renin-angiotensin system (RAS) inhibitors and beta-blockers in chronic Chagas&#xD;
      cardiomyopathy. This way, the investigators conducted a double-blind, placebo-controlled, and&#xD;
      randomized trial in 42 patients with Trypanosoma cruzi infection and cardiomyopathy. All&#xD;
      patients received enalapril (up-titrated to 20 mg BID) and spironolactone (25 mg QD).&#xD;
      Subsequently, the patients were randomly assigned to receive placebo (n = 20) or carvedilol&#xD;
      up-titrated to 25 mg BID (n = 19). The primary end points were change in left ventricular&#xD;
      ejection fraction (LVEF) after RAS inhibition and that after the addition of carvedilol. The&#xD;
      secondary end points were changes in other echocardiographic parameters, Framingham score,&#xD;
      quality of life (36-item Short-Form Health Survey), New York Heart Association class,&#xD;
      radiographic indices, brain natriuretic peptide levels, and chemokines as well as safety end&#xD;
      points.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Chagas cardiomyopathy (CCC) is an important cause of heart failure (HF) and sudden&#xD;
      death in Latin America.1 According to recent estimates, 13 million people worldwide are&#xD;
      infected with Trypanosoma cruzi, of whom 3.0 to 3.3 million are symptomatic.2 The incidence&#xD;
      rate is 200000 cases per year. Among those infected, 30% have clinical features of CCC and&#xD;
      15% ultimately develop overt left ventricular (LV) insufficiency-the main prognostic&#xD;
      determinant of the disease. In Chagas cardiomyopathy, the hemodynamic and neurohormonal&#xD;
      responses do not differ from those in other cardiomyopathies. This common pathophysiology&#xD;
      suggests that treatments shown to be effective by classic HF trials should be beneficial in&#xD;
      CCC. However, CCC has several specific characteristics, such as early cardiac denervation,&#xD;
      frequent ventricular arrhythmias, and several forms as well as grades of conduction&#xD;
      disturbances, including sinus bradycardia, complete atrioventricular block, and right&#xD;
      bundle-branch block. Morphologically, hypertrophy, dilatation, and severe fibrosis are&#xD;
      prominent. In 20% to 40% of cases, an apical ventricular aneurysm is present.1 These&#xD;
      peculiarities in combination lead to a high incidence of sudden death (60% of all deaths),&#xD;
      cardiac insufficiency, and ventricular remodeling. The responses of patients to the usual&#xD;
      drugs prescribed in HF could be different, and this perception has led to the suboptimal&#xD;
      dosing or lack of initiation of medical treatments that are of proven efficacy in patients&#xD;
      with other etiologies of HF. The underlying problem is that therapies that are effective in&#xD;
      patients with HF caused by non-chagasic cardiomyopathies, such as those with&#xD;
      renin-angiotensin system inhibitors (RASis) and h-blockers, have yet to be formally tested in&#xD;
      CCC. There are few clinical trials and no randomized study on this subject. Consequently, the&#xD;
      investigators evaluated the effects of optimizing treatment with enalapril and spironolactone&#xD;
      and then undertook a randomized trial of adding a h-blocker in the treatment of patients with&#xD;
      CCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in left ventricular ejection fraction</measure>
    <time_frame>Baseline, 4 months and 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Framingham score</measure>
    <time_frame>Baseline, 4 months and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life (36-item Short-Form Health Survey)</measure>
    <time_frame>Baseline, 4 months and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in New York Heart Association functional class</measure>
    <time_frame>Baseline, 4 months and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiothoracic ratio</measure>
    <time_frame>Baseline, 4 months and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in echocardiographic diastolic function indices</measure>
    <time_frame>Baseline, 4 months and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brain natriuretic peptide levels</measure>
    <time_frame>Baseline, 4 months and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in chemokines</measure>
    <time_frame>Baseline, 4 months and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in autoantibodies levels</measure>
    <time_frame>Baseline, 4 months and 8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chagas Cardiomyopathy</condition>
  <condition>Heart Failure</condition>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>RASi plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RAS inhibition was optimized and after patients were randomly assigned to receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RASi plus carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RASi plus carvedilol</intervention_name>
    <description>Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo</description>
    <arm_group_label>RASi plus carvedilol</arm_group_label>
    <other_name>Randomized</other_name>
    <other_name>Double blind</other_name>
    <other_name>Controlled</other_name>
    <other_name>Trial</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Criteria for inclusion were positivity for T cruzi as confirmed by 2 or more&#xD;
             serological tests (indirect immunofluorescence, ELISA, and/or indirect&#xD;
             hemagglutination) and having cardiomyopathy.&#xD;
&#xD;
          -  Cardiomyopathy was present when at least 3 of the following criteria were fulfilled:&#xD;
&#xD;
               -  LV enddiastolic diameter (LVDD) N55 mm&#xD;
&#xD;
               -  LVDD/body surface area &gt; 2.7cm/m2&#xD;
&#xD;
               -  LV ejection fraction (LVEF) &lt; 55%&#xD;
&#xD;
               -  QRS interval &gt; 120 ms&#xD;
&#xD;
               -  echocardiographic evidence of diffuse or segmental systolic wall motion&#xD;
                  abnormalities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria were being pregnant&#xD;
&#xD;
          -  Using any h-blocker&#xD;
&#xD;
          -  Having additional comorbidities (eg, hypertension, diabetes mellitus, thyroid&#xD;
             dysfunction, chronic obstructive pulmonary disease, asthma, and renal or hepatic&#xD;
             failure).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando A Botoni, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chagas Disease Outpatient Center of the Federal University of Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, Teixeira MM, Teixeira AL Jr, Reis AM, Dantas JB, Ferreira CS, Tavares WC Jr, Rocha MO. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J. 2007 Apr;153(4):544.e1-8.</citation>
    <PMID>17383291</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2012</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Minas Gerais</investigator_affiliation>
    <investigator_full_name>Antonio Luiz Pinho Ribeiro</investigator_full_name>
    <investigator_title>Director-General, Hospital das Cl√≠nicas, UFMG</investigator_title>
  </responsible_party>
  <keyword>Chagas cardiomyopathy,</keyword>
  <keyword>Renin-angiotensin system,</keyword>
  <keyword>Beta-blockers,</keyword>
  <keyword>Enalapril,</keyword>
  <keyword>Carvedilol,</keyword>
  <keyword>Renin-angiotensin system inhibitors,</keyword>
  <keyword>Brain natriuretic peptide level,</keyword>
  <keyword>Left ventricular ejection fraction,</keyword>
  <keyword>Chemokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Cardiomyopathy</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

